Published in Arch Otolaryngol Head Neck Surg on July 01, 2009
RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab. Radiat Oncol (2010) 0.93
Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy]. BMC Cancer (2011) 0.90
Raster-scanned carbon ion therapy for malignant salivary gland tumors: acute toxicity and initial treatment response. Radiat Oncol (2011) 0.83
[Salivary gland mucoepidermoid carcinoma: unusual variants with detection of the t(11,19)(q21;p13) translocation]. Pathologe (2009) 0.82
Survival outcomes of patients treated with hypofractionated stereotactic body radiation therapy for parotid gland tumors: a retrospective analysis. Front Oncol (2012) 0.80
Outcomes and prognostic factors in modern era management of major salivary gland cancer. Oral Oncol (2015) 0.79
IMRT and carbon ion boost for malignant salivary gland tumors: interim analysis of the COSMIC trial. BMC Cancer (2012) 0.78
Reirradiation of recurrent salivary gland malignancies with fractionated stereotactic body radiation therapy. J Radiat Oncol (2012) 0.78
Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. Radiat Oncol (2016) 0.76
Relapsed Acinic Cell Carcinoma of the Parotid Gland With Diffuse Distant Metastasis: Case Report With Literature Review. J Investig Med High Impact Case Rep (2016) 0.75
Locally Advanced Stage High-Grade Mucoepidermoid Carcinoma of Salivary Gland in a 9-Year-Old Girl: The Controversy of Adjuvant Therapy. Rare Tumors (2016) 0.75
Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation? Radiat Oncol (2016) 0.75
Management of salivary gland carcinomas - a review. Oncotarget (2016) 0.75
The Present and Future Opportunities of the Rare Cancer Network: An International Consortium for Advancement of Oncologic Care. Rare Tumors (2015) 0.75
IMRT with Stereotactic Body Radiotherapy Boost for High Risk Malignant Salivary Gland Malignancies: A Case Series. Front Oncol (2014) 0.75
Parotid carcinoma: Current diagnostic workup and treatment. Indian J Surg Oncol (2010) 0.75
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med (2003) 13.99
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol (2014) 5.80
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol (2010) 4.34
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med (2011) 3.83
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol (2012) 3.18
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol (2005) 2.88
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med (2015) 2.46
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol (2007) 2.39
Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA (2005) 2.37
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res (2004) 2.33
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol (2008) 2.18
Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol (2004) 2.14
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol (2009) 2.13
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol (2010) 2.12
Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol (2008) 2.11
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol (2009) 2.10
Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst (2013) 1.81
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80
Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg (2003) 1.76
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther (2008) 1.65
Head and neck cancers. J Natl Compr Canc Netw (2011) 1.64
Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol (2005) 1.63
Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys (2007) 1.54
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood (2007) 1.54
Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med (2013) 1.51
Sun protection at elementary schools: a cluster randomized trial. J Natl Cancer Inst (2010) 1.50
Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res (2003) 1.47
Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis (2012) 1.47
The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood (2005) 1.43
Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One (2010) 1.41
Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys (2009) 1.38
The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol (2003) 1.37
Distinguishing screening from diagnostic mammograms using Medicare claims data. Med Care (2014) 1.37
Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation. Br J Haematol (2003) 1.31
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res (2009) 1.25
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer (2010) 1.25
A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys (2009) 1.24
A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol (2004) 1.23
Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm (2008) 1.23
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. Prostate (2010) 1.19
Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys (2008) 1.18
Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol (2008) 1.16
Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest (2013) 1.15
Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer (2008) 1.15
Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg (2007) 1.15
Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol (2009) 1.14
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer (2010) 1.14
Thyroid carcinoma. J Natl Compr Canc Netw (2007) 1.13
Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res (2003) 1.12
Lipomatous tumors of the parapharyngeal space: case series and literature review. Arch Otolaryngol Head Neck Surg (2010) 1.08
Testicular defense systems: immune privilege and innate immunity. Cell Mol Immunol (2014) 1.05
Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res (2006) 1.05
Thyroid carcinoma. J Natl Compr Canc Netw (2005) 1.04
Synchronous global assessment of gene and protein expression in colorectal cancer progression. Genomics (2005) 1.04
Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation. Phytother Res (2014) 1.04
Complications of radiation therapy for head and neck cancers. The patient's perspective. Cancer Nurs (2002) 1.03
Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer (2008) 1.03
Head and neck cancer: recent advances and new standards of care. J Clin Oncol (2006) 1.02
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res (2006) 1.02
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res (2008) 1.01
On the lateral structure of model membranes containing cholesterol. Biochim Biophys Acta (2008) 1.01
A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting. Int J Nanomedicine (2012) 1.01
Head and neck cancers. J Natl Compr Canc Netw (2008) 1.01
Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am J Pathol (2012) 1.00
Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol (2009) 1.00
EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions. Clin Cancer Res (2013) 0.99
Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. Diagn Pathol (2012) 0.99
Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in children and youth. Diabetes Care (2012) 0.99
Assessment of toxicity in cooperative oncology clinical trials: the long and short of it. J Oncol Manag (2002) 0.99
Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother (2010) 0.97
Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin Colorectal Cancer (2004) 0.97
Medullary carcinoma. J Natl Compr Canc Netw (2010) 0.97
Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. Int J Radiat Oncol Biol Phys (2007) 0.97
Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation. Int J Radiat Oncol Biol Phys (2006) 0.93
Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol (2009) 0.93
Assessing health care use and cost consequences of a new screening modality: the case of digital mammography. Med Care (2012) 0.93
Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol (2011) 0.92
Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer. Cancer Epidemiol Biomarkers Prev (2009) 0.92
Penetrating craniofacial injury inflicted by a knife. J Trauma (2008) 0.91
Validation of a Medicare Claims-based Algorithm for Identifying Breast Cancers Detected at Screening Mammography. Med Care (2016) 0.91
Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia. Clin Colorectal Cancer (2007) 0.91
Effects of progressive muscular relaxation training on anxiety, depression and quality of life of endometriosis patients under gonadotrophin-releasing hormone agonist therapy. Eur J Obstet Gynecol Reprod Biol (2012) 0.89
Mammographic screening interval in relation to tumor characteristics and false-positive risk by race/ethnicity and age. Cancer (2013) 0.89
Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck (2013) 0.88
Bax-interacting factor-1 expression in prostate cancer. Clin Genitourin Cancer (2008) 0.87
Cancer in nonagenarians: profile, treatments and outcomes. Crit Rev Oncol Hematol (2010) 0.87